| Indicatie: | Nieuw gediagnosticeerde, niet eerder behandelde patienten met AML die niet in aanmerking komen voor intensieve chemotherapie |
| Studie: | ENHANCE |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Nieuw gediagnosticeerd MM en MRD-positief na het ondergaan van ASCT
≥18 jaar |
| Studie: | MagnetisMM |
| A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) vs lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Patients with previously untreated CLL
incl fit and unfit pts
incl.pts with del17p/TP53 mut
≥18 jaar |
| Studie: | Hovon 500 |
| A phase 3 multicentre, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukaemia (CLL) |
| Open in: | RdGG |
| Contact: | |
| Status: | OPEN |
|
| Indicatie: | Leeftijd ≥ 18 jaar |
| Studie: | CC-5013-MCL-005 |
| A Non-interventional, Post-authorization Safety Study of Patients with Relapsed or Refractrory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Previously untreated MCL ineligible for stem cell transplant |
| Studie: | Mangrove BGB3111-306 |
| 1e lijn/zanubrutinib+R vs R-benda
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | CLOSED |
|
| Indicatie: | Leeftijd 18-64 jaar |
| Studie: | LOXO-305-BTK-20019 |
| A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321) |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Leeftijd ≥18 jaar |
| Studie: | Hovon 140 |
| A Phase 3 multicenter, randomized, propective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus Rituximab plus Venetoclax (RVE) versus Obinutuzumab (GA101) plus Venetoclax GVE) versus Obinutuzumab plus Ibrutinib plus Venetoclax (GIVE) in fit patients with previously untreated chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP 53 mutation |
| Open in: | RdGG |
| Contact: | |
| Status: | OPEN |
|
| Indicatie: | CLL patiënten
leeftijd ≥18 jaar |
| Studie: | Hovon 159 Reveal |
| A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL) |
| Open in: | RdGG |
| Contact: | |
| Status: | OPEN |
|
| Indicatie: | Nieuw gediagnosticeerd
18-65 jaar
|
| Studie: | Hovon 138 Apollo |
| A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLine-based chemotherapy (AIDA regimen) for patients with newLy diagnosed, high-risk acute prOmyelocytic leukemia‘ |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | CLOSED |
|
| Indicatie: | SCT + CMV / EBV / AdV infection |
| Studie: | TRACE |
| Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial |
| Open in: | LUMC |
| Contact: | P.van_Balen@lumc.nl |
| Status: | OPEN |
|
